MoonLake Immunotherapeutics (MLTX) Stock Forecast & Price Target

Compare

589 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

MLTX Analyst Ratings

Moderate Buy

8 Buy

8 Hold

1 Sell

Based on 17 analysts giving stock ratings to

MoonLake

Immunotherapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

MLTX Stock 12 Month Forecast

Average Price Target

$17.92

▲(86.67% Upside)

Based on 17 Wall Street analysts offering 12 month price targets for MoonLake Immunotherapeutics in the last 3 months. The average price target is $17.92 with a high forecast of $65.00 and a low forecast of $5.00. The average price target represents a 86.67% change from the last price of $9.60.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","35":"$35","66":"$66","19.5":"$19.5","50.5":"$50.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":65,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$65.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":17.92,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$17.92</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$5.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,19.5,35,50.5,66],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.06,11.516923076923076,15.973846153846154,20.43076923076923,24.887692307692305,29.34461538461538,33.80153846153846,38.25846153846154,42.715384615384615,47.17230769230769,51.629230769230766,56.08615384615384,60.543076923076924,{"y":65,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.06,7.895384615384615,8.73076923076923,9.566153846153846,10.401538461538461,11.236923076923077,12.072307692307692,12.907692307692308,13.743076923076924,14.57846153846154,15.413846153846155,16.24923076923077,17.084615384615386,{"y":17.92,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.06,6.901538461538461,6.743076923076923,6.584615384615384,6.426153846153846,6.2676923076923075,6.109230769230769,5.950769230769231,5.792307692307692,5.633846153846154,5.475384615384615,5.316923076923077,5.158461538461538,{"y":5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":51.72,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.76,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":55.47,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54.15,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.99,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.76,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.35,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.44,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.16,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.61,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":52.92,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.56,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.06,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$65.00

Average Price Target$17.92

Lowest Price Target$5.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Andreas Argyrides

Oppenheimer

$104→$25

Buy

160.42%

Upside

Reiterated

10/07/25

MoonLake Immunotherapeutics price target lowered to $25 from $104 at OppenheimerMoonLake Immunotherapeutics price target lowered to $25 from $104 at Oppenheimer

Rami Katkhuda

LifeSci Capital

$75→$16

Buy

66.67%

Upside

Reiterated

10/04/25

LifeSci Capital Reaffirms Their Buy Rating on MoonLake Immunotherapeutics (MLTX)‘We are lowering our penetration for sonelokimab in HS and reducing its POS across indications, resulting in an updated PT of $16/share (previously $75/share)’

Ram Selvaraju

H.C. Wainwright

―

Hold

―

Downgraded

10/02/25

MoonLake Immunotherapeutics downgraded to Neutral from Buy at H.C. WainwrightMoonLake Immunotherapeutics downgraded to Neutral from Buy at H.C. Wainwright

Thomas Smith

Leerink Partners

$73→$14

Buy

45.83%

Upside

Reiterated

10/01/25

MoonLake Immunotherapeutics (MLTX) Receives a Buy from Leerink PartnersLowering our PT for MLTX to $14 (from $73) following disappointing Phase 3 results – we remain OP rated.

Serge Belanger

Needham

$66→$20

Buy

108.33%

Upside

Reiterated

09/30/25

Buy Rating on MoonLake Immunotherapeutics: Potential Beyond VELA Trials Amid Setbacks

Richard Law CFA

Goldman Sachs

Hold

-27.08%

Downside

Downgraded

09/30/25

Analysts Offer Insights on Healthcare Companies: MoonLake Immunotherapeutics (NASDAQ: MLTX) and Ionis Pharmaceuticals (NASDAQ: IONS)Hard to Find Excitement From Here, Our Reflection on VELA and Downgrade to Neutral with $7 PT

Clara Dong

Jefferies

Hold

-16.67%

Downside

Downgraded

09/30/25

MoonLake Immunotherapeutics (MLTX) was downgraded to a Hold Rating at Jefferies

Samantha Semenkow

Citi

$72→$5

Hold

-47.92%

Downside

Downgraded

09/30/25

Hold Rating for MoonLake Immunotherapeutics Amid Clinical and Financial Challenges

Julian Harrison

BTIG

―

Hold

―

Downgraded

09/29/25

MoonLake Immunotherapeutics downgraded to Neutral from Buy at BTIGMoonLake Immunotherapeutics downgraded to Neutral from Buy at BTIG

Yatin Suneja

Guggenheim

$80→$20

Buy

108.33%

Upside

Reiterated

09/29/25

Guggenheim cuts MoonLake Immunotherapeutics price target, removes as Best IdeaGuggenheim cuts MoonLake Immunotherapeutics price target, removes as Best Idea

Andy Chen

Wolfe Research

―

Sell

―

Downgraded

09/29/25

MoonLake Immunotherapeutics downgraded to Underperform from Peer Perform at Wolfe ResearchMoonLake Immunotherapeutics downgraded to Underperform from Peer Perform at Wolfe Research

Phil Nadeau

TD Cowen

―

Buy

―

Reiterated

09/29/25

TD Cowen Remains a Buy on MoonLake Immunotherapeutics (MLTX)with MLTX trading at a modest E.V. we remain Buy.

Kaveri Pohlman

Clear Street

$108→$12

Buy

25.00%

Upside

Reiterated

09/29/25

MoonLake price target lowered to $12 from $108 at Clear StreetMoonLake price target lowered to $12 from $108 at Clear Street

Yun Zhong

Wedbush

$80→$18

Buy

87.50%

Upside

Reiterated

09/29/25

Wedbush Reaffirms Their Buy Rating on MoonLake Immunotherapeutics (MLTX)

Alex Thompson CFA

Stifel Nicolaus

$77→$13

Hold

35.42%

Upside

Downgraded

09/28/25

MoonLake Immunotherapeutics: Hold Rating Due to Unfavorable Phase 3 Results and Uncertain Market Prospects

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Andreas Argyrides

Oppenheimer

$104→$25

Buy

160.42%

Upside

Reiterated

10/07/25

MoonLake Immunotherapeutics price target lowered to $25 from $104 at OppenheimerMoonLake Immunotherapeutics price target lowered to $25 from $104 at Oppenheimer

Rami Katkhuda

LifeSci Capital

$75→$16

Buy

66.67%

Upside

Reiterated

10/04/25

Ram Selvaraju

H.C. Wainwright

―

Hold

―

Downgraded

10/02/25

MoonLake Immunotherapeutics downgraded to Neutral from Buy at H.C. WainwrightMoonLake Immunotherapeutics downgraded to Neutral from Buy at H.C. Wainwright

Thomas Smith

Leerink Partners

$73→$14

Buy

45.83%

Upside

Reiterated

10/01/25

MoonLake Immunotherapeutics (MLTX) Receives a Buy from Leerink PartnersLowering our PT for MLTX to $14 (from $73) following disappointing Phase 3 results – we remain OP rated.

Serge Belanger

Needham

$66→$20

Buy

108.33%

Upside

Reiterated

09/30/25

Buy Rating on MoonLake Immunotherapeutics: Potential Beyond VELA Trials Amid Setbacks

Richard Law CFA

Goldman Sachs

Hold

-27.08%

Downside

Downgraded

09/30/25

Clara Dong

Jefferies

Hold

-16.67%

Downside

Downgraded

09/30/25

MoonLake Immunotherapeutics (MLTX) was downgraded to a Hold Rating at Jefferies

Samantha Semenkow

Citi

$72→$5

Hold

-47.92%

Downside

Downgraded

09/30/25

Hold Rating for MoonLake Immunotherapeutics Amid Clinical and Financial Challenges

Julian Harrison

BTIG

―

Hold

―

Downgraded

09/29/25

MoonLake Immunotherapeutics downgraded to Neutral from Buy at BTIGMoonLake Immunotherapeutics downgraded to Neutral from Buy at BTIG

Yatin Suneja

Guggenheim

$80→$20

Buy

108.33%

Upside

Reiterated

09/29/25

Guggenheim cuts MoonLake Immunotherapeutics price target, removes as Best IdeaGuggenheim cuts MoonLake Immunotherapeutics price target, removes as Best Idea

Andy Chen

Wolfe Research

―

Sell

―

Downgraded

09/29/25

MoonLake Immunotherapeutics downgraded to Underperform from Peer Perform at Wolfe ResearchMoonLake Immunotherapeutics downgraded to Underperform from Peer Perform at Wolfe Research

Phil Nadeau

TD Cowen

―

Buy

―

Reiterated

09/29/25

TD Cowen Remains a Buy on MoonLake Immunotherapeutics (MLTX)with MLTX trading at a modest E.V. we remain Buy.

Kaveri Pohlman

Clear Street

$108→$12

Buy

25.00%

Upside

Reiterated

09/29/25

MoonLake price target lowered to $12 from $108 at Clear StreetMoonLake price target lowered to $12 from $108 at Clear Street

Yun Zhong

Wedbush

$80→$18

Buy

87.50%

Upside

Reiterated

09/29/25

Wedbush Reaffirms Their Buy Rating on MoonLake Immunotherapeutics (MLTX)

Alex Thompson CFA

Stifel Nicolaus

$77→$13

Hold

35.42%

Upside

Downgraded

09/28/25

MoonLake Immunotherapeutics: Hold Rating Due to Unfavorable Phase 3 Results and Uncertain Market Prospects

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering MoonLake Immunotherapeutics

1 Month

xxx

Success Rate

16/26 ratings generated profit

Average Return

+12.60%

reiterated a xxx

rating 23 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 61.54% of your transactions generating a profit, with an average return of +12.60% per trade.

3 Months

xxx

Success Rate

17/26 ratings generated profit

Average Return

+27.18%

reiterated a xxx

rating 23 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 65.38% of your transactions generating a profit, with an average return of +27.18% per trade.

1 Year

Thomas SmithLeerink Partners

Success Rate

13/26 ratings generated profit

Average Return

+56.25%

reiterated a buy rating 23 days ago

Copying Thomas Smith's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +56.25% per trade.

2 Years

xxx

Success Rate

9/26 ratings generated profit

Average Return

+29.60%

reiterated a xxx

rating 23 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 34.62% of your transactions generating a profit, with an average return of +29.60% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

MLTX Analyst Recommendation Trends

Rating

Jun 25

Jul 25

Aug 25

Sep 25

Oct 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, MLTX has received 19 Buy Ratings, 5 Hold Ratings, and 1 Sell Ratings. MLTX average Analyst price target in the past 3 months is 17.92.

Each month's total comprises the sum of three months' worth of ratings.

MLTX Financial Forecast

MLTX Earnings Forecast

Next quarter’s earnings estimate for MLTX is -$0.88 with a range of -$0.99 to -$0.63. The previous quarter’s EPS was -$0.87. MLTX beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year MLTX has Preformed in-line its overall industry.

No data currently available

MLTX Sales Forecast

Next quarter’s sales forecast for MLTX is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. MLTX beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year MLTX has Preformed in-line its overall industry.

MLTX Stock Forecast FAQ

What is MLTX’s average 12-month price target, according to analysts?

Based on analyst ratings, MoonLake Immunotherapeutics’s 12-month average price target is 17.92.

What is MLTX’s upside potential, based on the analysts’ average price target?

MoonLake Immunotherapeutics has 86.67% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is MLTX a Buy, Sell or Hold?

MoonLake Immunotherapeutics has a consensus rating of Moderate Buy which is based on 8 buy ratings, 8 hold ratings and 1 sell ratings.

What is MoonLake Immunotherapeutics’s price target?

The average price target for MoonLake Immunotherapeutics is 17.92. This is based on 17 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $65.00 ,the lowest forecast is $5.00. The average price target represents 86.67% Increase from the current price of $9.6.

What do analysts say about MoonLake Immunotherapeutics?

MoonLake Immunotherapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 17 Wall Streets Analysts.

How can I buy shares of MLTX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

MoonLake Immunotherapeutics (MLTX) Stock Forecast & Price Target

MLTX Analyst Ratings

MLTX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering MoonLake Immunotherapeutics

MLTX Analyst Recommendation Trends

MLTX Financial Forecast

MLTX Earnings Forecast

MLTX Sales Forecast

MLTX Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts